Three-part virtual meeting series.
The role of TPO-RAs in blood disorders
In this three-part series, expert haematologists will discuss the use of TPO-RAs in ITP and SAA. There will be presentations, debates and case studies from leaders in the field, with time for you to be able to ask questions. The sessions are open to all clinicians working in haematology and are accessible via the registration sites below.
How to manage the refractory acquired SAA patient– a guide to diagnosing, managing and monitoring
Dr. Ronan Desmond, Tallaght University Hospital, Dublin
Tuesday 17th November 2020, 17:00
ITP in the real world; a multidisciplinary approach
Chair: Dr. Drew Provan, Royal London Hospital
Panel: Dr. Quentin Hill, Leeds, Dr. Vickie McDonald, Royal London Hospital, Rosie Davies, Haematology Nurse Specialist, Liverpool
Monday 14th December 2020, 17:00
After the meeting, the presentation slides and a recording of the meeting will be available for a limited time to registered users on this site to refer back to.
Novartis is truly committed to providing world-class education to our UK healthcare professionals. We recognise the value this meeting brings to a vast range of physicians including registrars, nurses, pharmacists and consultants. We hope that you can join us for this meeting series.
Indication: REVOLADE is indicated for the treatment of patients aged 1 year and above with primary ITP lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).1
REVOLADE is indicated in adult patients with chronic HCV infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy.1
REVOLADE is indicated in adult patients with acquired SAA who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation.1
This meeting is organised and funded by Novartis Pharmaceuticals UK Ltd and will contain company product information. Prescribing information will also be available at this meeting.
Abbreviations: HCV, hepatitis C virus; ITP, immune thrombocytopenia; SAA, severe aplastic anaemia; TPO-RA, thrombopoietin-receptor agonist.
- REVOLADE Summary of Product Characteristics.